ACADIA Pharmaceuticals Inc. (ACAD)

Environment story

ACADIA discloses minimal environmental data. The company mentions hazardous materials use in R&D and manufacturing but provides no quantified Scope 1, 2, or 3 emissions; no renewable energy percentage; and no net-zero target year. No major environmental controversies or litigation identified in filings. The company notes compliance with environmental, health, and safety laws but lacks verified decarbonization infrastructure investments. Absence of disclosed environmental metrics and targets results in a moderate score reflecting incomplete ESG transparency rather than active harm.

Social story

ACADIA discloses limited social metrics. No CEO-to-worker pay ratio disclosed. No evidence of union-suppression activities, strikes, or labor litigation within 24 months. No leadership diversity percentages disclosed in 10-K. Supply-chain ethics: ACADIA relies on third-party manufacturers and CROs; pharmaceutical API sourcing from international suppliers including China noted as a supply-chain risk, but no specific human-rights audits or controversies disclosed. The company emphasizes talent attraction and retention but does not disclose structured DEI programs, pay equity analyses, or EEO-1 data. Absence of negative indicators and reference to personnel investment justify a moderate-to-good score, but lack of transparency on diversity and pay equity limits full credit.

Governance story

ACADIA discloses no dual-class share structure, indicating single-class voting equity (positive for governance). Board independence percentage not disclosed in 10-K excerpt. No evidence of lobbying to weaken climate or consumer-protection regulations disclosed. No active antitrust, consumer-safety, or financial-fraud regulatory proceedings mentioned. The company operates under SOX, SEC rules, and Nasdaq governance standards and notes significant compliance costs. Patent and IP defense activities noted. No shareholder derivative suits or SEC consent decrees identified in 10-K. Governance structure appears standard for publicly traded biopharmaceutical firm. Absence of major governance controversies and absence of disclosed regulatory proceedings support moderate-to-good score; limited transparency on board composition prevents higher rating.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of ACADIA Pharmaceuticals Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open ACADIA Pharmaceuticals Inc. in the app for interactive charts and portfolio building.

More in Healthcare